NCI-2024-06081

A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd), A B7-H3 ANTIBODY-DRUG CONJUGATE (ADC), IN COMBINATION WITH ATEZOLIZUMAB WITH OR WITHOUT CARBOPLATIN AS FIRST-LINE INDUCTION OR MAINTENANCE, IN SUBJECTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)    

This PHASE 1B/2, MULTICENTER, OPEN-LABEL study is testing a combination of three treatments for Extensive-Stage Small Cell Lung Cancer (ES-SCLC). Ifinatamab Deruxtecan (I-DXd) is an antibody-drug conjugate (ADC), which is a type of drug that combines an antibody (a protein that can specifically target cancer cells) with a chemotherapy drug. The antibody in I-DXd targets a protein called B7-H3 on cancer cells, delivering the chemotherapy directly to the cancer cells to kill them while minimizing damage to healthy cells. Atezolizumab is an immune checkpoint inhibitor that blocks a protein on cancer cells, helping the immune system recognize and attack the cancer. Carboplatin is a chemotherapy drug that works by damaging the DNA of cancer cells, stopping them from growing and dividing. The study aims to see if combining these drugs can be a more effective treatment for this advanced form of lung cancer.

Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Cancer which has spread from the lungs to other areas of the body

open-label: Patients know which treatments are being given to them

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06362252

Clinical Trial Site: Columbia

To see all available clinical trials click here.